|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 94 No. 6 (September 15), 1999:
pp. 1840-1847
Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic
Indicators in Chronic Lymphocytic Leukemia
Rajendra N. Damle,
Tarun Wasil,
Franco Fais,
Fabio Ghiotto,
Angelo Valetto,
Steven L. Allen,
Aby Buchbinder,
Daniel Budman,
Klaus Dittmar,
Jonathan Kolitz,
Stuart M. Lichtman,
Philip Schulman,
Vincent P. Vinciguerra,
Kanti R. Rai,
Manlio Ferrarini, and
Nicholas Chiorazzi
From the Department of Medicine, North Shore University Hospital and
NYU School of Medicine, Manhasset, NY; the Department of Medicine, Long
Island Jewish Medical Center and the Albert Einstein College of
Medicine, New Hyde Park, NY; and the Division of Clinical Immunology,
Istituto Nazionale per la Ricerca sul Cancro, Dipartmento Oncologia
Clinica e Sperimentale, Universita di Genova, Genova, Italy.
Cellular immunophenotypic studies were performed on a cohort of
randomly selected IgM+ B-chronic lymphocytic leukemia
(B-CLL) cases for which Ig VH and VL gene
sequences were available. The cases were categorized based on V gene
mutation status and CD38 expression and analyzed for treatment history
and survival. The B-CLL cases could be divided into 2 groups. Those
patients with unmutated V genes displayed higher percentages of
CD38+ B-CLL cells ( 30%) than those with mutated V
genes that had lower percentages of CD38+ cells
(<30%). Patients in both the unmutated and the 30%
CD38+ groups responded poorly to continuous multiregimen
chemotherapy (including fludarabine) and had shorter survival. In
contrast, the mutated and the <30% CD38+ groups
required minimal or no chemotherapy and had prolonged survival. These
observations were true also for those patients who stratified to the
Rai intermediate risk category. In the mutated and the <30%
CD38+ groups, males and females were virtually equally
distributed, whereas in the unmutated and the 30%
CD38+ groups, a marked male predominance was found. Thus,
Ig V gene mutation status and the percentages of CD38+
B-CLL cells appear to be accurate predictors of clinical outcome in
B-CLL patients. These parameters, especially CD38 expression that can
be analyzed conveniently in most clinical laboratories, should be
valuable adjuncts to the present staging systems for predicting the
clinical course in individual B-CLL cases. Future evaluations of new
therapeutic strategies and drugs should take into account the different
natural histories of patients categorized in these manners.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Letters in Blood Online:
-
Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia
- Karim Maloum, Frédéric Davi, Hélène Merle-Béral, Otto Pritsch, Christian Magnac, Françoise Vuillier, Guillaume Dighiero, Xavier Troussard, Francesca F. Mauro, and Jacques Bénichou
Blood 2000 96: 377-379.
[Full Text]
[PDF]
-
CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia
- Ulf Thunberg, Anna Johnson, Göran Roos, Ingrid Thörn, Gerard Tobin, Jan Sällström, Christer Sundström, Richard Rosenquist, Franco Fais, Fabio Ghiotto, Rajendra Damle, Tarun Wasil, Nicholas Chiorazzi, Simona Zupo, and Manlio Ferrarini
Blood 2001 97: 1892-1894.
[Full Text]
[PDF]
-
CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia
- Zoltan Matrai, Ke Lin, Michael Dennis, Paul Sherrington, Mirko Zuzel, Andrew R Pettitt, and John C. Cawley
Blood 2001 97: 1902.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
D. Rossi, A. Zucchetto, F. M. Rossi, D. Capello, M. Cerri, C. Deambrogi, S. Cresta, S. Rasi, L. De Paoli, C. L. Bodoni, et al.
CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia
Haematologica,
October 1, 2008;
93(10):
1575 - 1579.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Kujawski, P. Ouillette, H. Erba, C. Saddler, A. Jakubowiak, M. Kaminski, K. Shedden, and S. N. Malek
Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia
Blood,
September 1, 2008;
112(5):
1993 - 2003.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Z. Rassenti, S. Jain, M. J. Keating, W. G. Wierda, M. R. Grever, J. C. Byrd, N. E. Kay, J. R. Brown, J. G. Gribben, D. S. Neuberg, et al.
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
Blood,
September 1, 2008;
112(5):
1923 - 1930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Proto-Siqueira, R. A. Panepucci, F. P. Careta, A. Lee, A. Clear, K. Morris, C. Owen, E. G. Rizzatti, W. A. Silva Jr, R. P. Falcao, et al.
SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL
Blood,
July 15, 2008;
112(2):
394 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Malavasi, S. Deaglio, A. Funaro, E. Ferrero, A. L. Horenstein, E. Ortolan, T. Vaisitti, and S. Aydin
Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology
Physiol Rev,
July 1, 2008;
88(3):
841 - 886.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Hamblin
Ligandless receptors find a role
Blood,
July 1, 2008;
112(1):
2 - 3.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Muzio, B. Apollonio, C. Scielzo, M. Frenquelli, I. Vandoni, V. Boussiotis, F. Caligaris-Cappio, and P. Ghia
Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy
Blood,
July 1, 2008;
112(1):
188 - 195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Li, S. Ding, J. Pan, M. A. Shakhmatov, E. Kashentseva, J. Wu, Y. Li, S.-j. Soong, N. Chiorazzi, and R. S. Davis
FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia
Blood,
July 1, 2008;
112(1):
179 - 187.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hallek, B. D. Cheson, D. Catovsky, F. Caligaris-Cappio, G. Dighiero, H. Dohner, P. Hillmen, M. J. Keating, E. Montserrat, K. R. Rai, et al.
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Blood,
June 15, 2008;
111(12):
5446 - 5456.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Aydin, D. Rossi, L. Bergui, G. D'Arena, E. Ferrero, L. Bonello, P. Omede, D. Novero, F. Morabito, A. Carbone, et al.
CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome?
Blood,
June 15, 2008;
111(12):
5646 - 5653.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Crowther-Swanepoel, R. Wild, G. Sellick, M. J. S. Dyer, F. R. Mauro, R. J. G. Cuthbert, V. Jonsson, E. Matutes, C. Dearden, J. Wiley, et al.
Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL
Blood,
June 15, 2008;
111(12):
5691 - 5693.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. M. Patten, A. G. S. Buggins, J. Richards, A. Wotherspoon, J. Salisbury, G. J. Mufti, T. J. Hamblin, and S. Devereux
CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment
Blood,
May 15, 2008;
111(10):
5173 - 5181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Ghia, S. Jain, G. F. Widhopf II, L. Z. Rassenti, M. J. Keating, W. G. Wierda, J. G. Gribben, J. R. Brown, K. R. Rai, J. C. Byrd, et al.
Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection
Blood,
May 15, 2008;
111(10):
5101 - 5108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Friedrichs, S. Siegel, M. Kloess, A. Barsoum, J. Coggin Jr., J. Rohrer, I. Jakob, M. Tiemann, K. Heidorn, C. Schulte, et al.
Humoral Immune Responses against the Immature Laminin Receptor Protein Show Prognostic Significance in Patients with Chronic Lymphocytic Leukemia
J. Immunol.,
May 1, 2008;
180(9):
6374 - 6384.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hewamana, S. Alghazal, T. T. Lin, M. Clement, C. Jenkins, M. L. Guzman, C. T. Jordan, S. Neelakantan, P. A. Crooks, A. K. Burnett, et al.
The NF-{kappa}B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target
Blood,
May 1, 2008;
111(9):
4681 - 4689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lanemo Myhrinder, E. Hellqvist, E. Sidorova, A. Soderberg, H. Baxendale, C. Dahle, K. Willander, G. Tobin, E. Backman, O. Soderberg, et al.
A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies
Blood,
April 1, 2008;
111(7):
3838 - 3848.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Cutrona, M. Colombo, S. Matis, M. Fabbi, M. Spriano, V. Callea, E. Vigna, M. Gentile, S. Zupo, N. Chiorazzi, et al.
Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells
Haematologica,
March 1, 2008;
93(3):
413 - 422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Agrawal, F.-T. Liu, C. Wiseman, S. Shirali, H. Liu, D. Lillington, M.-Q. Du, D. Syndercombe-Court, A. C. Newland, J. G. Gribben, et al.
Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia
Blood,
March 1, 2008;
111(5):
2790 - 2796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Roos, A. Krober, P. Grabowski, D. Kienle, A. Buhler, H. Dohner, R. Rosenquist, and S. Stilgenbauer
Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia
Blood,
February 15, 2008;
111(4):
2246 - 2252.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Gachard, A. Salviat, C. Boutet, C. Arnoulet, F. Durrieu, B. Lenormand, S. Lepretre, S. Olschwang, F. Jardin, M. Lafage-Pochitaloff, et al.
Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method
Haematologica,
February 1, 2008;
93(2):
215 - 223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Murray, N. Darzentas, A. Hadzidimitriou, G. Tobin, M. Boudjogra, C. Scielzo, N. Laoutaris, K. Karlsson, F. Baran-Marzsak, A. Tsaftaris, et al.
Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis
Blood,
February 1, 2008;
111(3):
1524 - 1533.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Saddler, P. Ouillette, L. Kujawski, S. Shangary, M. Talpaz, M. Kaminski, H. Erba, K. Shedden, S. Wang, and S. N. Malek
Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia
Blood,
February 1, 2008;
111(3):
1584 - 1593.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Baskar, K. Y. Kwong, T. Hofer, J. M. Levy, M. G. Kennedy, E. Lee, L. M. Staudt, W. H. Wilson, A. Wiestner, and C. Rader
Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia
Clin. Cancer Res.,
January 15, 2008;
14(2):
396 - 404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Longo, L. Laurenti, S. Gobessi, S. Sica, G. Leone, and D. G. Efremov
The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells
Blood,
January 15, 2008;
111(2):
846 - 855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Gattei, P. Bulian, M. I. Del Principe, A. Zucchetto, L. Maurillo, F. Buccisano, R. Bomben, M. Dal-Bo, F. Luciano, F. M. Rossi, et al.
Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia
Blood,
January 15, 2008;
111(2):
865 - 873.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. W. Hauswirth and U. Jager
Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia
Haematologica,
January 1, 2008;
93(1):
14 - 19.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Kipps
Chronic Lymphocytic Leukemia: Prognostic Markers and Revised Criteria for Treatment and Response Assessment
ASCO Educational Book,
January 1, 2008;
2008(1):
286 - 290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Gribben
The Role of Stem Cell Transplantation in Chronic Lymphocytic Leukemia
ASCO Educational Book,
January 1, 2008;
2008(1):
291 - 296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. N. Damle, S. Temburni, C. Calissano, S. Yancopoulos, T. Banapour, C. Sison, S. L. Allen, K. R. Rai, and N. Chiorazzi
CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells
Blood,
November 1, 2007;
110(9):
3352 - 3359.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Willimott, M. Baou, S. Huf, S. Deaglio, and S. D. Wagner
Regulation of CD38 in proliferating chronic lymphocytic leukemia cells stimulated with CD154 and interleukin-4
Haematologica,
October 1, 2007;
92(10):
1359 - 1366.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Stamatopoulos, N. Meuleman, B. Haibe-Kains, H. Duvillier, M. Massy, P. Martiat, D. Bron, and L. Lagneaux
Quantification of ZAP70 mRNA in B Cells by Real-Time PCR Is a Powerful Prognostic Factor in Chronic Lymphocytic Leukemia
Clin. Chem.,
October 1, 2007;
53(10):
1757 - 1766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Durig, P. Ebeling, F. Grabellus, U. R. Sorg, M. Mollmann, P. Schutt, J. Gothert, L. Sellmann, S. Seeber, M. Flasshove, et al.
A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease
Cancer Res.,
September 15, 2007;
67(18):
8653 - 8661.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Joshi, G. V. Hegde, J. D. Dickinson, A. K. Mittal, J. C. Lynch, J. D. Eudy, J. O. Armitage, P. J. Bierman, R. G. Bociek, M. P. Devetten, et al.
ATM, CTLA4, MNDA, and HEM1 in High versus Low CD38 Expressing B-Cell Chronic Lymphocytic Leukemia
Clin. Cancer Res.,
September 15, 2007;
13(18):
5295 - 5304.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Stilgenbauer, S. Sander, L. Bullinger, A. Benner, E. Leupolt, D. Winkler, A. Krober, D. Kienle, P. Lichter, and H. Dohner
Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival
Haematologica,
September 1, 2007;
92(9):
1242 - 1245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. V. Abruzzo, L. L. Barron, K. Anderson, R. J. Newman, W. G. Wierda, S. O'Brien, A. Ferrajoli, M. Luthra, S. Talwalkar, R. Luthra, et al.
Identification and Validation of Biomarkers of IgVH Mutation Status in Chronic Lymphocytic Leukemia Using Microfluidics Quantitative Real-Time Polymerase Chain Reaction Technology
J. Mol. Diagn.,
September 1, 2007;
9(4):
546 - 555.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Gaeta, H. R. Malming, K. J.L. Jackson, M. E. Bain, P. Wilson, and A. M. Collins
iHMMune-align: hidden Markov model-based alignment and identification of germline genes in rearranged immunoglobulin gene sequences
Bioinformatics,
July 1, 2007;
23(13):
1580 - 1587.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Sabattini, R. Orduz, C. Campidelli, P. L. Zinzani, V. Callea, S. Zupo, G. Cutrona, F. Morabito, M. Ferrarini, and S. Pileri
B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens
J. Clin. Pathol.,
June 1, 2007;
60(6):
627 - 632.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Josefsson, C. H. Geisler, H. Leffers, J. H. Petersen, M. K. Andersen, J. Jurlander, and A. M. Buhl
CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia
Blood,
June 1, 2007;
109(11):
4973 - 4979.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
